P. Peter Ghoroghchian, M.D., Ph.DFounder

United States - Philadelphia, Pennsylvania

Dr. P. Peter Ghoroghchian is an American physician-scientist, bioengineer and serial biotechnology entrepreneur. Prior to his current position as CEO of Latus Bio, he most recently served as co-founder, President and CEO of Ceptur Therapeutics – a privately-held and ventured-backed genetic medicines company developing oligonucleotide therapeutics. He was previously Senior Vice President and Head of Therapeutic Development at Repertoire Immune Medicines (2019-2020) – a venture-backed and clinical-stage company in the Flagship Pioneering portfolio, Chief Technology Officer at Poseida Therapeutics (2016-2019) – a publicly-traded (NASDAQ: PSTX), clinical-stage and non-viral gene therapy and CAR-T company, as well as co-founder and Chief Scientific Officer at Vindico NanoBioTechnology (2009-2016) – a privately-held biotechnology company based on his own research in non-viral DNA and RNA delivery (acquired by Poseida in 2016). Earlier in his career, Dr. Ghoroghchian was an attending physician in the Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute as well as the Charles W. and Jennifer C. Johnson Clinical Investigator in the Koch Institute for Integrative Cancer Research at MIT. He earned his B.S. in Chemical Engineering from MIT followed by his Ph.D. and M.D. degrees from the University of Pennsylvania. After medical school, Dr. Ghoroghchian completed residency training in Internal Medicine at the Brigham and Women’s Hospital as well as fellowship training in Hematology and Adult Medical Oncology at the Dana-Farber Cancer Institute and at the Massachusetts General Hospital.